Abstract
FTY720 is a recently approved first line therapy for relapsing forms of multiple sclerosis. In this context, FTY720 is a pro-drug, with its anti-multiple sclerosis, immunosuppressive effects largely elicited following its phosphorylation by sphingosine kinase 2 and subsequent modulation of G protein-coupled sphingosine 1-phosphate (S1P) receptor 1 that induces lymphopenia by altering lymphocyte trafficking. A number of other biological effects of FTY720 have, however, been described, including considerable evidence that this drug also has anti-cancer properties. These other effects of FTY720 are independent of S1P receptors, and appear facilitated by modulation of a range of other recently described protein targets by nonphosphorylated FTY720. Here, we review the direct targets of FTY720 that contribute to its anti-cancer properties. We also discuss other recently described protein effectors that, in combination with S1P receptors, appear to contribute to its immunosuppressive effects.
Keywords: Apoptosis, cancer, FTY720, fingolimod, lymphopenia, lysophospholipid, sphingosine, sphingosine 1-phosphate, therapeutic drug, Gilenya™, myriocin, immunosuppressive activity, immuno-suppressants, toxicity, multiple sclerosis
Current Molecular Medicine
Title:Molecular Targets of FTY720 (Fingolimod)
Volume: 12 Issue: 10
Author(s): M.R. Pitman, J.M. Woodcock, A.F. Lopez and S.M. Pitson
Affiliation:
Keywords: Apoptosis, cancer, FTY720, fingolimod, lymphopenia, lysophospholipid, sphingosine, sphingosine 1-phosphate, therapeutic drug, Gilenya™, myriocin, immunosuppressive activity, immuno-suppressants, toxicity, multiple sclerosis
Abstract: FTY720 is a recently approved first line therapy for relapsing forms of multiple sclerosis. In this context, FTY720 is a pro-drug, with its anti-multiple sclerosis, immunosuppressive effects largely elicited following its phosphorylation by sphingosine kinase 2 and subsequent modulation of G protein-coupled sphingosine 1-phosphate (S1P) receptor 1 that induces lymphopenia by altering lymphocyte trafficking. A number of other biological effects of FTY720 have, however, been described, including considerable evidence that this drug also has anti-cancer properties. These other effects of FTY720 are independent of S1P receptors, and appear facilitated by modulation of a range of other recently described protein targets by nonphosphorylated FTY720. Here, we review the direct targets of FTY720 that contribute to its anti-cancer properties. We also discuss other recently described protein effectors that, in combination with S1P receptors, appear to contribute to its immunosuppressive effects.
Export Options
About this article
Cite this article as:
Pitman M.R., Woodcock J.M., Lopez A.F. and Pitson S.M., Molecular Targets of FTY720 (Fingolimod), Current Molecular Medicine 2012; 12 (10) . https://dx.doi.org/10.2174/156652412803833599
DOI https://dx.doi.org/10.2174/156652412803833599 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potential Application of Biomaterials in Cardiac Stem Cell Therapy
Current Medicinal Chemistry Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Killing Glioma ‘Stem-like’ Cells via Drug-Induced Relocation of Endosomal Urokinase Proteins
Anti-Cancer Agents in Medicinal Chemistry Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals
Current Pharmaceutical Design Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy Ribonucleotide Reductase: A Mechanistic Portrait of Substrate Analogues Inhibitors
Current Medicinal Chemistry TNF-Related Apoptosis-Inducing Ligand (TRAIL) as a Pro-Apoptotic Signal Transducer with Cancer Therapeutic Potential
Current Pharmaceutical Design Targeting Heme for the Identification of Cytotoxic Agents
Anti-Cancer Agents in Medicinal Chemistry Allelic Imbalances of the egfr Gene as Key Events in Breast Cancer Progression – the Concept of Committed Progenitor Cells
Current Cancer Drug Targets Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets Current Uses of Robotic Surgery for the Treatment of Benign Adnexal Conditions
Current Women`s Health Reviews MiR-134, Mediated by IRF1, Suppresses Tumorigenesis and Progression by Targeting VEGFA and MYCN in Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Design and Characterization of Mucoadhesive Gelatin-Ethylcellulose Microparticles for the Delivery of Curcumin to the Bladder
Current Drug Delivery Mouse Strains for Prostate Tumorigenesis Based on Genes Altered in Human Prostate Cancer
Current Drug Targets Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms
Current Pharmaceutical Design Noteworthy Secondary Metabolites Naphthoquinones – their Occurrence, Pharmacological Properties and Analysis
Current Pharmaceutical Analysis Mechanism-Based Treatment in Chronic Neuropathic Pain: The Role of Antidepressants
Current Pharmaceutical Design